Press Release

Global Epilepsy Drugs Market to grow with a CAGR of 3.09%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Epilepsy Drugs Market.

 

According to TechSci Research report, “Global Epilepsy Drugs Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Epilepsy Drugs Market has valued at USD 6.95 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.09% through 2028.  This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market. Emerging therapies are drivers for the global epilepsy drugs market. These therapies represent new and innovative approaches to the treatment of epilepsy, often with the goal of improving seizure control, reducing side effects, and enhancing the quality of life for individuals living with the condition. Pharmaceutical companies are continuously researching and developing new epilepsy drugs with innovative mechanisms of action. These drugs aim to provide better seizure control and improved tolerability compared to existing options. Emerging therapies may be tailored to individual patients through precision medicine approaches. Genetic testing and biomarker identification help identify the most appropriate drugs and treatment plans for specific epilepsy subtypes. Advances in biotechnology and understanding of epilepsy's underlying mechanisms have led to the development of biological therapies, such as gene therapies and monoclonal antibodies, which target specific molecular pathways involved in epilepsy. Medical cannabis and cannabinoid-based treatments have gained attention as potential options for epilepsy management, particularly for individuals with drug-resistant epilepsy. Some cannabinoids, like cannabidiol (CBD), have received regulatory approval for specific epilepsy syndromes. Techniques like vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and transcranial magnetic stimulation (TMS) are emerging as adjuvant therapies to help reduce seizures or improve seizure control when medications alone are ineffective. Dietary therapies, including the ketogenic diet, are considered emerging options for epilepsy management, particularly in pediatric cases. These therapies may be used in conjunction with or as alternatives to drug treatments.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Epilepsy Drugs Market.”

 

 Epilepsy is a persistent neurological condition characterized by recurrent seizures resulting from abnormal electrical brain activity. It is a chronic noncommunicable medical condition. Seizures come in various forms, each involving involuntary movements that can impact specific body regions or the entire body. Treatment choices encompass medications, including first-generation, second-generation, and third-generation drugs. In November 2020, UCB, a global pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for VIMPAT (lacosamide) CV to be used as an adjunctive therapy for the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients aged four and older. This approval also includes VIMPAT injection for intravenous use in children aged four and older. PGTCS is a specific type of seizure that impacts the entire brain, involving both brain hemispheres from the outset and leading to muscle stiffness and convulsions lasting for a few minutes. Epilepsy is a common symptom associated with various chronic brain disorders. It stands as the fourth most prevalent neurological condition globally, affecting approximately 65 million individuals. Epilepsy can affect people of all ages, ethnic backgrounds, and genders and is characterized by one or more unprovoked epileptic seizures, which carry a risk of further seizures.Stigma and misinformation are significant challenges in the global epilepsy drugs market and in the broader context of epilepsy management. These challenges can have various negative impacts on individuals with epilepsy and the overall healthcare landscape. Stigma and misconceptions about epilepsy can lead to delayed diagnosis and treatment. People may be hesitant to seek medical help due to fear of social stigma, discrimination, or a lack of understanding about the condition. Delayed treatment can result in uncontrolled seizures and more severe health consequences. Individuals with epilepsy often face social isolation, bullying, and discrimination. Stigmatization can lead to emotional distress, anxiety, depression, and low self-esteem. These psychosocial effects can impact a patient's overall well-being and may affect their adherence to medication and treatment plans. Stigma can limit the opportunities and quality of life for people with epilepsy. Discrimination in education, employment, and social interactions may lead to social exclusion and economic hardships. Stigma and misinformation can contribute to medication non-adherence. Some individuals may stop taking their epilepsy drugs due to perceived social stigma or misinformation about the safety and effectiveness of treatment. Healthcare providers may face challenges in educating and supporting patients with epilepsy due to prevailing misinformation and societal biases. Addressing stigma and providing accurate information is essential for effective patient care.

Global Epilepsy Drugs Market is segmented based on Drugs, Distribution Channel, and by region.  Based on the Drugs, Global Epilepsy Drugs Market is segmented into First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics. First-generation anti-epileptic drugs (AEDs), also known as traditional or older AEDs, are a group of medications that were among the first to be developed and approved for the treatment of epilepsy. These drugs have been in use for several decades and were initially introduced in the mid-20th century. While they remain important in epilepsy management, newer, second-generation AEDs have been developed with improved safety and efficacy profiles. First-generation AEDs act on various mechanisms within the brain to prevent or reduce epileptic seizures. First-generation AEDs are known for their side effects, which can vary among different drugs but may include drowsiness, dizziness, memory problems, mood changes, and reduced cognitive function. Long-term use of some of these drugs may lead to more severe side effects, such as liver toxicity, bone health issues, or skin reactions. Many first-generation AEDs can interact with other medications, potentially affecting their efficacy or leading to adverse effects. Drug interactions are an important consideration for patients and healthcare providers. Based on Region, North America held the largest share in the Global Epilepsy Drugs Market. North America has well-established epilepsy advocacy organizations and awareness campaigns that help reduce the stigma associated with epilepsy and educate the public and healthcare professionals. Increased awareness often leads to more people seeking diagnosis and treatment. The highly competitive pharmaceutical market in North America can lead to aggressive marketing and promotion of epilepsy drugs, resulting in increased sales and market dominance. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) play a crucial role in the approval and oversight of epilepsy drugs. The efficient and transparent regulatory processes in North America contribute to the availability of a wide range of epilepsy medications. North America has a large pool of neurologists and healthcare professionals with expertise in epilepsy diagnosis and treatment. This expertise ensures that patients receive the most appropriate and up-to-date care.

 

Some of the major companies operating in the Global Epilepsy Drugs Market include:

  • Novartis AG
  • GlaxoSmithKline plc
  • Sanofi S.Aa
  • UCB S.A.
  • Abbott Laboratories
  • Bausch Health Companies, Inc
  • Viatris Inc.
  • Johnson & Johnson
  • Sumitomo Pharma Co., Ltd
  • H. Lundbeck A/S

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.


“Certain areas, particularly in North America, are projected to exert significant demand for Epilepsy Drugs. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Epilepsy Drugs Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Epilepsy Drugs Market by Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Epilepsy Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Epilepsy Drugs Market.


 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com

Relevant News